Influence of metabolic syndrome on risk stratification in hypertensive patients: differences between 2003 and 2007 ESH-ESC guidelines

Abstract

Objective: To investigate the influence of metabolic syndrome (MS) on risk stratification and ulterior classification in hypertensive patients at entry into a hypertension unit by comparing the criteria of ESH-ESC 2003 and 2007 guidelines.

Methods: 720 consecutive patients attending a hospital-located hypertension unit were included in the study. They were classified with or without MS according to the ATP-III 2005 report. Patients underwent repeated office BP measurements and routine blood/urine examinations. In addition ultrasensitive CRP (uCRP), echocardiogram, fasting insulin, urinary albumin excretion were determined and HOMA index was calculated.

Results: The prevalence of MS was 58.8 %. Abdominal obesity and fasting glucose were the most prevalent components of MS, and HDL-cholesterol the least prevalent. MS group had higher levels of LDL-cholesterol and higher prevalence of left ventricular hypertrophy and microalbuminuria. Patients with MS also presented a significant elevation in uCRP, fasting insulin and HOMA. BP was controlled in 55.6%. When we applied the 2003 guideline, 48.9% patients showed a high or very high added cardiovascular risk. With the applications of the 2007 guide the prevalence of this two categories reach 73.9%.

Conclusions: A significant difference in the risk pattern distribution is found when MS is considered in risk stratification in our hypertensive population. The accompanying increase in the levels of other cardiovascular risk factors and in the prevalence of target organ damage justifies the global intervention on cardiovascular risk recommended by 2007 ESH-ESC guidelines.

Keywords

hypertension guidelines metabolic syndrome cardiovascular risk stratification insulin resistance

References

Ärnlöv, J. , Pencina, M.J. , Nam, B.-H. , Meigs, J.B. , Fox, C.S. , Levy, D. et al. (2005) Relations of insulin sensitivity to longitudinal blood pressure tracking. Circulation 112: 1719-1727.

Banegas, J.R. , Segura, J. , Ruilope, L.M. , Luque, M. , García-Robles, R. , Campo, M. et al. (2004) Blood pressure control and physician management of hypertension in hospital hypertension units in Spain. Hypertension 43: 1338-1344.

Burattini, R. , Di Nardo, F. , Boemi, M. and Fumelli, P. ( 2006) Deterioration of insulin sensitivity and glucose effectiveness with age and hypertension. Am J Hypertens 19: 98-102.

Cockroft, D.W. and Gault, M.H. ( 1976) Prediction of creatinine clearance from serum creatinine . Nephron 16: 31-41.

Cordero, A. , Laclaustra, M. , Leon, M. , Grima, A. , Casasnovas, J.A. , Luengo, E. et al. (2006) Prehypertension is associated with insulin resistance state and not with an initial renal function impairment. A Metabolic Syndrome in active subjects in Spain (MESYAS) Registry Substudy. Am J Hypertens 19: 189-196.

Cuspidi, C. , Meani, S. , Fusi, V. , Severgini, B. , Valerio, C. , Catini, E. et al. (2004) Metabolic syndrome and target organ damage in untreated essential hypertensives. J Hyperten 22: 1991-1998.

Dekker, J.M. , Girman, C. , Rhodes, T. , Nijpels, G. , Stehouwer, C.D.A. , Bouter, L.M. et al. (2005) Metabolic Syndrome and 10-Year Cardiovascular Disease Risk in the Hoorn Study. Circulation 112: 666-673.

Devereux, R.B. and Reichek, W.E. ( 1997) Echocardigraphic determination of left ventricular mass in man: Anatomic validation of the method. Circulation 55: 613-618.

Ferrannini, E. ( 2006) Is insulin resistance the cause of the metabolic syndrome ? Ann Med 38: 42-51.

10.

Ford, E.S. , Giles, W.H. and Dietz, W.H. ( 2002) Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 287: 356-359.

11.

Ford, E.S. ( 2005) Prevalence of the Metabolic Syndrome Defined by the International Diabetes Federation Among Adults in the US. Diabetes Care 28: 2745-2749.

12.

Gómez-Gerique, J.A. , Gutiérrez-Fuentes, J.A. , Montoya, M.T. , Porres, A. , Rueda, A. , Avellaneda, A. et al. (1999) Lipid profile of the Spanish population: the DRECE (diet and risk of cardiovascular disease in Spain) study. (DRECE study group]. Med Clin 113: 730-735.

13.

Grundy, S.M. , Cleeman, J.I. , Daniels, S.R. , Donato, K.A. , Eckel, R.H. , Franflin, B.A. et al. (2005) Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Executive summary. Circulation 112: 2735-2752.

14.

Guidelines Committee. (2003) European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 21: 1011-1053.

15.

Ingelsson, E. , Arnlov, J. , Lind, L. and Sundstrom, J. ( 2006) The metabolic syndrome and risk for heart failure in middle-aged men. Heart 92: 1409-1413.

16.

Kannel, W.B. ( 2000) Risk stratification in hypertension: new insights from the Framinghan study. Am J Hypertens 13(Suppl. 1): S3-S10.

17.

Kurl, S. , Laukkanen, J.A. , Niskanen, L. , Laaksonen, D. , Sivenius, J. , Nyyssonen, K. et al. (2006) Metabolic syndrome and the risk of stroke in middle-aged. Stroke 37: 806-811.

18.

Lorenzo, C. , Okoloise, M. , Williams, K. , Stern, M.P. and Haffner, S.M. ( 2003) The metabolic syndrome as predictor of type 2 diabetes . Diabetes Care 26: 3153-3159.

19.

Lorenzo, C. , Williams, K. , Hunt, K.J. and Haffner, S.M. ( 2006) Trend in the prevalence of the metabolic syndrome and its impact on cardiovascular disease incidence: The San Antonio Heart Study . Diabetes Care 29: 625-630.

20.

Mancia, G. , Bombelli, M. , Corrao, G. , Facchetti, R. , Madotto, F. , Giannattasio, C. et al. (2007a) Metabolic syndrome in the Pressioni Arteriose Monitorate E Loro Associazioni (PAMELA) study: daily life blood pressure, cardiac damage, and prognosis. Hypertension 49: 40-47.

21.

Mancia, G. , De Backer, G. , Dominiczak Zifcova, R. , Fagard, R. , Germano, G. et al. (2007b) 2007 Guidelines for the management of arterial hypertension. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 25: 1105-1187.

22.

Matthews, D.R. , Hosker, J.P. , Rudenski, A.S. , Naylor, B.A. , Treacher, D.F. and Turner, R.C. ( 1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412-419.

23.

Mulè, G. , Nardi, E. , Cottone, S. , Cusimano, P. , Volpe, V. , Piazza, G. et al. (2005) Influence of metabolic syndrome on hypertension-related target organ damage. J Intern Med 257: 503-513.

24.

Nigam, A. , Bourassa, M.G. , Fortier, A. , Guertin, M.-C. and Tardif, J.-C. ( 2006) The metabolic syndrome and its components and the long-term risk of death in patients with coronary heart disease. Am Heart J 151: 514-521.

25.

Pi-Sunyer, F.X. , Aronne, L.J. and Heshmati, H.M. ( 2006) Effect of rimonabant, a cannabinoi-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patient: RIO-North America: randomized controlled trial. J Am Med Assoc 295: 761-775.

26.

Rantala, A.O. , Karma, H. , Lilja, M. , Savolainen, M.J. , Reunanen, A. and Kesäniemi, Y.A. ( 1999) Prevalence of the metabolic syndrome in drug-treated hypertensive patients and control subject. J Intern Med 245: 163-174.

27.

Schillaci, G. , Pirro, M. , Vaudo, G. , Gemelli, F. , Marchesi, S. , Porcellati, C. et al. (2004) Prognostic value of the metabolic syndrome in essential hypertension. J Am Coll Cardiol 43: 1817-1822.

28.

Schindler, T.H. , Cardenas, J. , Pior, J.O. , Facta, A.D. , Kreissl, M.C. , Zhang, X.-L. et al. (2006) Relationship between increasing body weight, insulin resistance, inflammation, adipocytokine leptin, and coronary circulatory function. J Am Coll Cardiol 47: 1188-1195.

29.

Tan, C.E. , Ma, S. , Wai, D. , Chew, S.K. and Tai, E.S. ( 2004) Can we apply the National Cholesterol Education Program Adult Treatment Panel definition of the metabolic syndrome to Asians? Diabetes Care 27: 1182-1186.